Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jun;10(6):743-53.
doi: 10.1586/erv.11.70.

From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer

Ravi A Madan  1 , Jeanny B Aragon-Ching, James L Gulley, William L Dahut
Affiliations
Review

From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer

Ravi A Madan et al. Expert Rev Vaccines. 2011 Jun.

Abstract

Therapeutic options for patients with metastatic castration-resistant prostate cancer are increasing, spurring an urgent need to better understand which treatments are best for individual patients. The recent approval of a first-in-class agent, sipuleucel-T, has intensified this need. This therapeutic cancer vaccine has demonstrated a survival advantage in two Phase III trials, but does not alter progression in the short term. Therefore, a new therapeutic approach for patients with metastatic castration-resistant prostate cancer is taking shape, based on broader understanding of available therapies. This new clinical approach seeks to maximize patient benefit from treatment, minimize associated toxicities, and may have far-reaching implications for other therapeutic cancer vaccines currently in clinical development.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proposed therapeutic approach to patients with metastatic castration-resistant prostate cancer. Second-line hormonal therapy includes androgen receptor antagaonists and ketoconazole. †For patients with asymptomatic metastatic disease or metastatic patients who have progressed on docetaxel, investigational agents would also be appropriate in the context of a clinical trial. ‡The relative benefits of each sequence of cabazitaxel and abiraterone have yet to be clinically evaluated. Other approaches that could be considered as secondary options under certain circumstances include mitoxantrone and prednisone, estrogens and bone-seeking radionuclides.
See this image and copyright information in PMC

References

    1. Huggins C, Bergenstal DM. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res. 1952;12(2):134–141. - PubMed
    1. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–244. - PubMed
    1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512. - PubMed
    1. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520. - PubMed
    1. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–790. - PMC - PubMed

Websites

    1. FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer. [cited June 2010]; http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm210174.htm.
    1. Food and Drug Administration Sipuleucel-T brief document (BLA STN 1251970) [cited July 2008]; http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4291B1_01.pdf.
    1. PROSTVAC: Therapeutic vaccine candidate for the treatment of advanced prostate cancer [cited June 2010]; http://www.bavarian-nordic.com/pipeline/prostvac.aspx.
    1. Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer. [cited December 2010]; http://clinicaltrials.gov/ct2/show/NCT01145508?term=mcneel+prostate&rank=5.
    1. FDA Approves New Treatment for Advanced Prostate Cancer [cited July 2010]; http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm216143.htm.

Publication types

MeSH terms